Ibritumomab Tiuxetan and Pasireotide Extended-Release Injection
Determining the interaction of Ibritumomab Tiuxetan and Pasireotide Extended-Release Injection and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: ibritumomab
Brand name: Y-90 Zevalin, In-111 Zevalin
Synonyms: Ibritumomab
Generic Name: pasireotide
Brand name: Signifor, Signifor LAR
Synonyms: Pasireotide
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Ibritumomab Tiuxetan-Pasireotide Injection
- Ibritumomab Tiuxetan-Pasireotide Subcutaneous
- Ibritumomab Tiuxetan-Patanase
- Ibritumomab Tiuxetan-Patiromer
- Ibritumomab Tiuxetan-Patiromer Sorbitex Calcium
- Ibritumomab Tiuxetan-Pavacot
- Pasireotide Extended-Release Injection-Ibrutinib
- Pasireotide Extended-Release Injection-Ibrutinib Capsules
- Pasireotide Extended-Release Injection-Ibrutinib Tablets
- Pasireotide Extended-Release Injection-Ibu
- Pasireotide Extended-Release Injection-IBU Tablets
- Pasireotide Extended-Release Injection-Ibu-2